GB8827024D0 - Nanbv diagnostics & vaccines - Google Patents

Nanbv diagnostics & vaccines

Info

Publication number
GB8827024D0
GB8827024D0 GB8827024A GB8827024A GB8827024D0 GB 8827024 D0 GB8827024 D0 GB 8827024D0 GB 8827024 A GB8827024 A GB 8827024A GB 8827024 A GB8827024 A GB 8827024A GB 8827024 D0 GB8827024 D0 GB 8827024D0
Authority
GB
United Kingdom
Prior art keywords
vaccines
nanbv
diagnostics
nanbv diagnostics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB8827024A
Other versions
GB2212511B (en
GB2212511A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27537644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB8827024(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of GB8827024D0 publication Critical patent/GB8827024D0/en
Publication of GB2212511A publication Critical patent/GB2212511A/en
Application granted granted Critical
Publication of GB2212511B publication Critical patent/GB2212511B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
GB8827024A 1987-11-18 1988-11-18 Hepatitis c virus Expired - Lifetime GB2212511B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12271487A 1987-11-18 1987-11-18
US13988687A 1987-12-30 1987-12-30
US16107288A 1988-02-26 1988-02-26
US19126388A 1988-05-06 1988-05-06
US26358488A 1988-10-26 1988-10-26

Publications (3)

Publication Number Publication Date
GB8827024D0 true GB8827024D0 (en) 1988-12-21
GB2212511A GB2212511A (en) 1989-07-26
GB2212511B GB2212511B (en) 1992-01-22

Family

ID=27537644

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8827024A Expired - Lifetime GB2212511B (en) 1987-11-18 1988-11-18 Hepatitis c virus

Country Status (3)

Country Link
GB (1) GB2212511B (en)
SG (1) SG102092G (en)
YU (1) YU48038B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US6861212B1 (en) 1987-11-18 2005-03-01 Chiron Corporation NANBV diagnostics and vaccines
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
US7166287B1 (en) 1989-12-18 2007-01-23 Glaxo Wellcome Inc. Viral agent
CH684594A5 (en) 1989-12-18 1994-10-31 Wellcome Found viral agent.
US6194140B1 (en) * 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
US6312889B1 (en) 1990-04-04 2001-11-06 Chiron Corporation Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US6172189B1 (en) * 1990-08-24 2001-01-09 Abbott Laboratories Hepatitis C assay utilizing recombinant antigens
JP2655205B2 (en) * 1991-03-26 1997-09-17 デイド、インターナショナル、インコーポレイテッド Assay for non-A non-B hepatitis
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
RU2148587C1 (en) * 1991-06-24 2000-05-10 Чирон Корпорейшн Polypeptide and method of its synthesis, reagent for immuno-analysis, method of assay of antibody presence, method of induction of immune response
ES2210235T3 (en) * 1992-01-31 2004-07-01 Abbott Laboratories MAMPHERE EXPRESSION SYSTEMS FOR HCV PROTEINS.
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US7070790B1 (en) 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5610009A (en) * 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
DE69526636D1 (en) * 1994-07-29 2002-06-13 Innogenetics Nv CLEANED HEPATITIS-C-VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
CN1214244C (en) 2000-06-15 2005-08-10 希龙公司 HCV antigen/antibody combination assay
WO2017004022A2 (en) * 2015-06-29 2017-01-05 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
CN107286237B (en) * 2017-08-07 2020-04-03 广州泰诺迪生物科技有限公司 Acquisition and application of anti-hepatitis C virus antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464474A (en) * 1980-07-09 1984-08-07 Connaught Laboratories Limited Non-A, non-B hepatitis assay and vaccine
CA1168579A (en) * 1981-02-11 1984-06-05 Philippe Maupas (Deceased) Non-a, non-b hepatitis virus
US4542016A (en) * 1981-03-27 1985-09-17 Institut Merieux Non-a non-b hepatitis surface antigen useful for the preparation of vaccines and methods of use
FR2502154A1 (en) * 1981-03-30 1982-09-24 Trepo Christian PROCESS FOR PREPARING ANTIGENS FOR VIRAL HEPATITIS NANB, AND APPLICATION TO THE REAGENT FOR THE DIAGNOSIS AND PROGNOSIS OF INFECTIONS CAUSED BY VIRAL HEPATITIS VIRUSES
NZ222465A (en) * 1986-11-07 1992-11-25 Pasteur Institut Nanb (non a, non b hepatitis viral) antigen
US4895976A (en) * 1988-05-23 1990-01-23 E. I. Du Pont De Nemours And Company Preparation of 4-pentanoates by isomerization

Also Published As

Publication number Publication date
GB2212511B (en) 1992-01-22
SG102092G (en) 1992-12-24
GB2212511A (en) 1989-07-26
YU213888A (en) 1991-02-28
YU48038B (en) 1996-10-18

Similar Documents

Publication Publication Date Title
GB8827024D0 (en) Nanbv diagnostics & vaccines
GR900300069T1 (en) Nanbv diagnostics and vaccines
EP0256878A3 (en) Vaccines
GB8907914D0 (en) Vaccine preparation
HU885826D0 (en) Preparations absorbable through the mycoderm
GB8628072D0 (en) Flavivirus antigen
ZA88149B (en) Anti-reproductive vaccines
GB8702691D0 (en) Vaccines
GB8921470D0 (en) Vaccines
ZA872532B (en) Combined vaccine
ZW22487A1 (en) Vaccine
ZA874847B (en) Oncornavirus vaccines
GB8704647D0 (en) Vaccine
GB8615068D0 (en) Vaccines
RO101205B1 (en) Anilino-furamidine preparation method
GB8912496D0 (en) Vaccines
IL88420A0 (en) Nanbv diagnostics and vaccines
HRP940493B1 (en) Nanbv diagnostics and vaccines
ZA888669B (en) Nanbv diagnostics and vaccines
GB8621081D0 (en) Vaccines
ZA882001B (en) Vaccines
GB8725519D0 (en) Vaccines
GB8716632D0 (en) Vaccines
GB8712829D0 (en) Vaccines
GB8723834D0 (en) Dental posts

Legal Events

Date Code Title Description
732 Registration of transactions, instruments or events in the register (sect. 32/1977)
775B Specification amended (sect. 75/1977)
SP Amendment (slips) printed
775L Amendment of patent in infringement or revocation proceedings. application to amend not proceeded with (sect. 75/1977)
SP Amendment (slips) printed
SP Amendment (slips) printed
PE20 Patent expired after termination of 20 years

Expiry date: 20081117